Vertiv Holdings Option Alert: Sep 19 $90 Puts at the Bid: 1280 vs 115 OI

Vertiv Holdings Option Alert: Sep 19 $90 Puts at the Bid: 1280 @ $9.55 vs 115 OI; Ref=$103.195

Vertiv Holdings Option Alert: May 16 $100 Puts at the Bid: 760 vs 112 OI

Vertiv Holdings Option Alert: May 16 $100 Puts at the Bid: 760 @ $9.2 vs 112 OI; Ref=$103.5075

Vertiv Holdings Option Alert: Sep 19 $135 Calls at the Ask: 900 vs 519 OI

Vertiv Holdings Option Alert: Sep 19 $135 Calls at the Ask: 900 @ $8.97 vs 519 OI; Ref=$103.75

Vertiv Holdings Option Alert: Mar 28 $85 Puts at the Bid: 6685 vs 7184 OI

Vertiv Holdings Option Alert: Mar 28 $85 Puts at the Bid: 6685 @ $0.78 vs 7184 OI; Ref=$106.0

Vertiv Hldgs Option Alert: May 16 $110 Puts at the Ask: 2000 vs 297 OI

Vertiv Hldgs Option Alert: May 16 $110 Puts at the Ask: 2000 @ $12.8 vs 297 OI; Ref=$107.745

Vertiv Hldgs Option Alert: Mar 28 $85 Puts at the Bid: 7135 vs 18 OI

Vertiv Hldgs Option Alert: Mar 28 $85 Puts at the Bid: 7135 @ $1.03 vs 18 OI; Ref=$107.64

Vertiv Holdings (NYSE:VRT) Azioni

VERTIV HOLDINGS CO-A

Vertiv Holdings

Vertiv Hldgs

Vertiv has roots tracing back to 1946 when its founder, Ralph Liebert, developed an air-cooling system for mainframe data rooms. As computers started making their way into commercial applications in 1965, Liebert developed one of the first computer room air conditioning, or CRAC, units, enabling the precise control of temperature and humidity. The firm has slowly expanded its data center portfolio through internal product development and the acquisition of thermal and power management products like condensers, busways, and switches. Vertiv has global operations today; its products can be found in data centers in most regions throughout the world.

Nvidia Stock Had A Bad Week After DeepSeek Unveiled Its New Model In January—Now CEO Jensen Huang Says Investors Are Misreading AI’s Future Impact- 'Obviously, That Paradigm Is Wrong' NS

Equities

News

Markets

AMZN

GOOG

GOOGL

MSFT

NVDA

TSLA

Il titolo perde terreno dopo il keynote, ma l&#39;analista di Deepwater Asset Management resta ottimista sul futuro dell&#39;IA.

NVIDIA crolla nonostante l&#39;IA: Gene Munster &#34;Io Ci Credo&#34;, ecco perché

Media

Trading Ideas

Jim Cramer raccomanda un&#39;azione imperdibile: scopri perché questo titolo è considerato un affare da non lasciarsi scappare ora.

Jim Cramer: questo titolo è un affare da non lasciarsi scappare

Vertiv Holdings, LLC Class A Common Stock

Vertiv Holdings Co

Venus Reward Token

Vestin Realty Mortgage II Inc

Veritec Inc

INDIGENOUS BLOOM HEMP CRP by INDIGENOUS BLOOM HEMP CORP

Indigenous Bloom Hemp Corp

VARTECH SYSTEMS INC by Vartech Systems Inc.

Vartech Systems Inc

GraniteShares 2x Long VRT Daily ETF

Virtus Investment Partners, Inc. Common Stock

Virtus Investment Partners Inc

VIATAR CTC SOLUTIONS INC by Viatar CTC Solutions Inc.

Veritiv Corp Com

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

Nextdoor Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIND#NYSE">KIND</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $54.18 million which beat the analyst consensus estimate of $53.12 million by 1.98 percent. This is a 1.94 percent increase over sales of $53.15 million the same period last year.

Earnings

Earnings Beats

KIND

Nextdoor Holdings Q1 EPS $(0.06) Beats $(0.07) Estimate, Sales $54.18M Beat $53.12M Estimate

OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.45) by 13.33 percent. This is a 30 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $52.41 million which beat the analyst consensus estimate of $51.68 million by 1.41 percent. This is a 17.29 percent increase over sales of $44.69 million the same period last year.

KIDS

OrthoPediatrics Q1 Adj. EPS $(0.39) Beats $(0.45) Estimate, Sales $52.41M Beat $51.68M Estimate

Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) affirms FY2025 sales outlook from $51.60 million-$55.00 million to $51.60 million-$55.00 million vs $52.55 million estimate.

Guidance

Laird Superfood Affirms FY2025 Sales Guidance of $51.60M-$55.00M vs $52.55M Est

KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) reported quarterly sales of $9.63 million which beat the analyst consensus estimate of $8.87 million by 8.62 percent. This is a 17.53 percent increase over sales of $8.20 million the same period last year.

KRMD

KORU Medical Systems Q1 Sales $9.63M Beat $8.87M Estimate

Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) raises FY2025 sales outlook from $2.02 billion-$2.04 billion to $2.02 billion-$2.04 billion vs $2.02 billion estimate.

PAYC

Paycom Software Raises FY2025 Sales Guidance of $2.02B-$2.04B vs $2.02B Est

Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) reported quarterly earnings of $2.80 per share which beat the analyst consensus estimate of $2.56 by 9.37 percent. This is a 8.11 percent increase over earnings of $2.59 per share from the same period last year. The company reported quarterly sales of $530.50 million which beat the analyst consensus estimate of $524.95 million by 1.06 percent. This is a 6.13 percent increase over sales of $499.88 million the same period last year.

Paycom Software Q1 Adj. EPS $2.80 Beats $2.56 Estimate, Sales $530.50M Beat $524.95M Estimate

<ul>
<li>The Company reaffirmed full-year 2025 guidance3 and expects net sales in the range of $17.2 to $17.6 billion. Operating EBITDA1 is expected to be $3.6 to $3.8 billion. Operating EPS1 is expected to be $2.70 to $2.95 per share.</li>
<li>The Company plans to repurchase approximately $1 billion of shares during 2025</li>
</ul>

CTVA

Corteva Affirms FY2025 Adj EPS Guidance of $2.70-$2.95 vs $2.95 Est; Affirms FY2025 Sales Guidance of $17.20B-$17.60B vs $17.33B Est

Movie theater company AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) reported first-quarter financial results<a href="https://www.benzinga.com/earnings"> after market close.</a>
Here are the highlights.
What Happened: AMC reported first-quarter revenue of $862.5 million, down 9.3% year-over-year. The total beat a Street consensus estimate of $837.1 million according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0507">from Benzinga Pro.</a>
The company reported an adjusted loss of 58 cents per share for the quarter, beating a Street consensus estimate of a loss of 59 cents per share.
"Anyone trying to draw any conclusions about the success or appeal of movie theaters from the results of the first quarter of 2025 is likely to be mistaken, because the industrywide domestic box office in Q1 was in our view a distorting anomaly that has already corrected itself," AMC CEO Adam Aron said.
Aron said the company grew per-patron operating metrics, including an all-time first quarter record for U.S. admissions revenue per patron. The AMC CEO highlighted the success of programs like AMC Stubs loyalty and the A-List subscription programs in the quarter.
Total attendance was 41.9 million in the first quarter, down 10.1% year-over-year. U.S. attendance was 26.9 million, down 11.8% year-over-year, while international attendance of 15.0 million was down 7.1% year-over-year.
AMC ended the first quarter with $378.7 million in cash.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/12/42750888/top-anticipated-2025-movies-for-big-screen-success-and-stocks-investors-should-watch">Top Anticipated 2025 Movies For Big Screen Success And Stocks Investors Should Watch</a>
 What's Next: Aron highlighted the future growth for AMC and the movie theater sector with a strong lineup of blockbusters in 2025 and 2026, echoing comments from past years.
"We continue to believe that moviegoing demand for the balance of 2025 and all of 2026 will show great strength," Aron said.
While the first three months of 2025 were the lowest box office totals since 1996, excluding the Covid-impacted years, Aron said the turnaround started in April 2025.
"Since April 1, movie theater demand has been booming. The April 2025 industry-wide domestic box office was double that of April 2024."
Aron said May is currently pacing at double the rate of a year ago.
"AMC is playing on offense again," Aron added, when highlighting the company's investments in more premium theaters.
Aron predicts that AMC can continue to recover from the challenges of recent years.
"We are optimistic that we will get done what needs to be done, and that AMC is poised to capture the momentum for a strengthening 2025 and 2026, and what we believe will be an even brighter future beyond."
AMC Price Action: AMC stock is up 1.5% to $2.76 in after-hours trading versus a 52-week trading range of $2.45 to $11.88.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/05/39010959/amc-ceo-says-were-still-here-how-taylor-swift-popcorn-buckets-help-movie-theater-from-going">AMC CEO Says &#8216;We&#8217;re Still Here&#8217;: How Taylor Swift, Popcorn Buckets Help Movie Theater From Going &#8216;Kaplooey&#8217;</a></li>
</ul>
Photo: Shutterstock

Entertainment

Movers

AMC Q1 Earnings Highlights: Double Beat, CEO Highlights 2025, 2026 Slate As Box Office Doubles In April

PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) reported quarterly sales of $1.58 million which missed the analyst consensus estimate of $3.60 million by 56.08 percent.

Earnings Misses

PureCycle Technologies Q1 Sales $1.58M Miss $3.60M Estimate

SEMR

SEMrush Hldgs Sees Q2 Sales $108.200M-$109.200M vs $108.89M Est

American States Water (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWR#NYSE">AWR</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.67 by 4.48 percent. This is a 12.9 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $148.01 million which beat the analyst consensus estimate of $145.85 million by 1.48 percent. This is a 9.44 percent increase over sales of $135.25 million the same period last year.

American States Water Q1 Adj. EPS $0.70 Beats $0.67 Estimate, Sales $148.01M Beat $145.85M Estimate

Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $0.88 by 28.41 percent. This is a 26.97 percent increase over earnings of $0.89 per share from the same period last year. The company reported quarterly sales of $4.42 billion which missed the analyst consensus estimate of $4.54 billion by 2.70 percent. This is a 1.60 percent decrease over sales of $4.49 billion the same period last year.

Corteva Q1 Adj. EPS $1.13 Beats $0.88 Estimate, Sales $4.42B Miss $4.54B Estimate

Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 69.23 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $279.54 million which missed the analyst consensus estimate of $283.27 million by 1.32 percent. This is a 1.35 percent increase over sales of $275.81 million the same period last year.

GTBIF

Green Thumb Industries Q1 EPS $0.04, Inline, Sales $279.54M Miss $283.27M Estimate

SEMrush Hldgs Q1 EPS $0.01 Misses $0.02 Estimate, Sales $105.02M Beat $104.36M Estimate

Vermilion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VET#NYSE">VET</a>) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.24 by 70.83 percent. This is a 600 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $396.27 million which missed the analyst consensus estimate of $554.60 million by 28.55 percent. This is a 5.13 percent increase over sales of $376.93 million the same period last year.

Vermilion Energy Q1 EPS $0.07 Misses $0.24 Estimate, Sales $396.27M Miss $554.60M Estimate

Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) reported quarterly losses of $(2.49) per share which beat the analyst consensus estimate of $(2.61) by 4.6 percent. This is a 2.05 percent decrease over losses of $(2.44) per share from the same period last year. The company reported quarterly sales of $2.55 million which beat the analyst consensus estimate of $180.00 thousand by 1.32K percent.

KRRO

Korro Bio Q1 EPS $(2.49) Beats $(2.61) Estimate, Sales $2.55M Beat $180.00K Estimate

Kennedy-Wilson Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KW#NYSE">KW</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.19) by 57.89 percent. This is a 257.89 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $128.30 million which missed the analyst consensus estimate of $160.27 million by 19.95 percent. This is a 5.94 percent decrease over sales of $136.40 million the same period last year.

Kennedy-Wilson Holdings Q1 EPS $(0.30) Misses $(0.19) Estimate, Sales $128.30M Miss $160.27M Estimate

Veeco Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) is looking for Q2 Adj EPS of $0.12-$0.32 vs $0.34 analyst estimate. sees sales of $135.000 million-$165.000 million vs $167.60 million analyst estimate.

VECO

Veeco Instruments Sees Q2 Adj EPS $0.12-$0.32 vs $0.34 Est; Sees Sales $135.000M-$165.000M vs $167.60M Est

Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) affirms FY2025 GAAP EPS guidance from $6.15-$6.35 to $6.15-$6.35 vs $6.25 analyst estimate..

Chesapeake Utilities Affirms FY2025 GAAP EPS Guidance of $6.15-$6.35 vs $6.25 Est

Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.81) by 17.28 percent. This is a 61.02 percent decrease over losses of $(0.59) per share from the same period last year.

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
12:58 PMFeb 20, 2025	PUT	$90.00	Sep 19, 2025	134	1280	1280	1113	115	TRADE	BULLISH
12:24 PMFeb 20, 2025	PUT	$100.00	May 16, 2025	8	822	760	734	112	TRADE	BULLISH
11:09 AMFeb 20, 2025	CALL	$135.00	Sep 19, 2025	134	0	900	0	519	TRADE	BULLISH
09:55 AMFeb 20, 2025	PUT	$85.00	Mar 28, 2025	-41	500	6685	7	7184	TRADE	BULLISH
12:46 PMFeb 19, 2025	PUT	$110.00	May 16, 2025	8	2022	2000	681	297	TRADE	BEARISH
10:21 AMFeb 14, 2025	PUT	$85.00	Mar 28, 2025	-41	7135	7135	39639	18	TRADE	BULLISH

Comments

Vertiv Holdings

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO